Skip to main content
Year archive

TELCON RF PHARMACEUTICAL. Inc. — 2021 filings

All 36 regulatory filings released by TELCON RF PHARMACEUTICAL. Inc. (200230) in 2021, sourced directly from the official regulator.

36 Filings
2021 Period
2021 filings (36)
Filing Released Lang
전환청구권행사
Share Issue/Capital Change
2021-12-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-12-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification
2021-12-22 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings
2021-12-15 Korean
전환가액의조정
Capital/Financing Update
2021-11-30 Korean
분기보고서 (2021.09)
Interim / Quarterly Report 9M 2021
2021-11-12 Korean
전환가액의조정
Share Issue/Capital Change
2021-11-01 Korean
전환가액의조정
Share Issue/Capital Change
2021-09-30 Korean
전환가액의조정
Share Issue/Capital Change
2021-08-31 Korean
반기보고서 (2021.06)
Interim / Quarterly Report H1 2021
2021-08-13 Korean
투자판단관련주요경영사항(COVID-19 치료제 Lenzilumab의 식약처 임상(제1상)시험 계획(IND) 승인)
Legal Proceedings Report
2021-07-22 Korean
전환가액의조정
Capital/Financing Update
2021-06-30 Korean
[기재정정]분기보고서 (2020.03)
Regulatory Filings Q1 2020
2021-06-18 Korean
[기재정정]반기보고서 (2020.06)
Interim / Quarterly Report H1 2020
2021-06-18 Korean
[기재정정]분기보고서 (2020.09)
Interim / Quarterly Report 9M 2020
2021-06-18 Korean
[기재정정]감사보고서제출(2020사업연도)
Audit Report / Information FY 2020
2021-06-18 Korean
[기재정정]사업보고서 (2020.12)
Audit Report / Information FY 2020
2021-06-18 Korean
전환가액의조정
Capital/Financing Update
2021-05-31 Korean
[기재정정]감사보고서제출(2019사업연도 재발행)
Audit Report / Information FY 2019
2021-05-28 Korean
[기재정정]감사보고서제출(2020사업연도)
Audit Report / Information FY 2020
2021-05-28 Korean
[기재정정]사업보고서 (2019.12)
Annual Report FY 2020
2021-05-28 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Q1 2021
2021-05-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2021-04-30 Korean
[기재정정]사업보고서 (2020.12)
Annual Report FY 2020
2021-03-31 Korean
[기재정정]사업보고서 (2020.12)
Annual Report FY 2020
2021-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements
2021-03-30 Korean
감사보고서제출
Audit Report / Information FY 2020
2021-03-22 Korean
사업보고서 (2020.12)
Annual Report FY 2020
2021-03-22 Korean
주주총회소집결의
AGM Information
2021-03-02 Korean
주주총회소집공고
Proxy Solicitation & Information Statement
2021-03-02 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release FY 2020
2021-03-02 Korean
전환가액의조정
Share Issue/Capital Change
2021-03-02 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement
2021-03-02 Korean
주주총회집중일개최사유신고
AGM Information
2021-03-02 Korean
전환가액의조정
Share Issue/Capital Change
2021-02-01 Korean
투자판단관련주요경영사항(COVID-19 치료제 Lenzilumab의 식약처 가교임상시험 계획 (IND) 승인 신청)
Regulatory Filings
2021-01-25 Korean